<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39396944</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Healthcare resource utilisation and costs in infants with confirmed respiratory syncytial virus infections: a national population cohort study.</ArticleTitle><Pagination><StartPage>1152</StartPage><MedlinePgn>1152</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09971-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Respiratory syncytial virus (RSV) is the leading cause of severe respiratory infections in infants worldwide, significantly affecting their health and contributing to the global healthcare burden. We aimed to examine healthcare resource utilisation patterns and costs for infants under one year old with confirmed RSV infection across subgroups of different gestational ages and health conditions and the cost implications of RSV infections over time, thereby demonstrating the economic burden of the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study utilised nationwide claims data from the Korea Health Insurance Review and Assessment Service for infants under one year of age with confirmed RSV infection in the first year of life from January 2017 to April 2022. The infants were stratified into three subgroups based on their gestational age and health status: unhealthy preterm, healthy preterm, and full-term infants. A descriptive analysis was conducted to estimate healthcare utilization by type of resource and costs related to the treatment of RSV.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 93,585 RSV infections identified, 31,206 patients met the inclusion criteria; these included 963 unhealthy preterm, 1,768 healthy preterm and 28,475 full-term infants. In our study, 76.3% of the infants with confirmed RSV infection required intensive care, including hospitalisation and more critical interventions such as intensive care unit (ICU) or mechanical ventilation (MV). The total average cost of RSV management was notably higher for unhealthy preterm infants ($ 6,325; 95% confidence interval (CI): $ 5,484-7,165) than for healthy preterm ($ 1,134; 95% CI: $ 1,006 - 1,261) and full-term infants ($ 606; 95% CI: 583-630). Our findings confirmed a significant epidemiological and economic burden, with infants at greater risk-shorter gestational age and poorer health conditions. Furthermore, we observed a marked increase in the total average cost of RSV management during COVID-19, reflecting the complex interplay between RSV and pandemic-related healthcare dynamics.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings provide evidence for the significant economic burden of RSV infection among infants, with considerable disparities based on gestational age and health status subgroups. However, RSV prevention policies should also recognise that healthy preterm or full-term infants who receive intensive care face a significant disease burden.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Han</LastName><ForeName>Hyun Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ryu</LastName><ForeName>Dahye</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ju Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Semin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712 , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Hae Sun</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea. haesun.suh@khu.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, 02447, Republic of Korea. haesun.suh@khu.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. haesun.suh@khu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21153MFDS601</GrantID><Agency>Ministry of Food and Drug Safety</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="Y">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007234" MajorTopicYN="N">Infant, Premature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005865" MajorTopicYN="N">Gestational Age</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006295" MajorTopicYN="N">Health Resources</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="N">Respiratory Syncytial Virus, Human</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Healthcare costs</Keyword><Keyword MajorTopicYN="N">Healthcare resource utilisation</Keyword><Keyword MajorTopicYN="N">Preterm infants</Keyword><Keyword MajorTopicYN="N">Respiratory syncytial virus</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39396944</ArticleId><ArticleId IdType="pmc">PMC11472633</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09971-0</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09971-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Y, XinBlau D, MCaballero M, TFeikin D, RGill C, JMadhi S, AOmer S, BSimões E, AFCampbell. Harry. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613574</ArticleId><ArticleId IdType="pubmed">35598608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti C, Greca AD, Bertoncelli D, Rubini M, Tchana B. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study: Palivizumab prophylaxis in children with congenital heart disease. Ital J Pediatr. 2023;49(1):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9835345</ArticleId><ArticleId IdType="pubmed">36631870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavunda K, Jiang X, Ambrose CS. Prevalence and clinical characteristics of perinatal chronic lung disease by infant gestational age. J Neonatal Perinat Med. 2021;14(1):43–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990434</ArticleId><ArticleId IdType="pubmed">32474477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenmoe S, Kengne-Nde C, Modiyinji AF, La Rosa G, Njouom R. Comparison of health care resource utilization among preterm and term infants hospitalized with human respiratory Syncytial Virus infections: a systematic review and meta-analysis of retrospective cohort studies. PLoS ONE. 2020;15(2):e0229357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7034889</ArticleId><ArticleId IdType="pubmed">32084214</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltema NM, Elisabeth EPouw, JuliëtteBlanken M, ORovers M, MNaaktgeboren C, AMazur N, IWildenbeest. Joanne Gvan Der Ent, Cornelis KBont, Louis J. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respiratory Med. 2018;6(4):257–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">29500030</ArticleId></ArticleIdList></Reference><Reference><Citation>Smithgall M, Maykowski P, Zachariah P, Oberhardt M, Vargas CY, Reed C, et al. Epidemiology, clinical features, and resource utilization associated with respiratory syncytial virus in the community and hospital. Influenza Other Respir Viruses. 2020;14(3):247–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182604</ArticleId><ArticleId IdType="pubmed">32077641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Therapy. 2016;5:271–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019979</ArticleId><ArticleId IdType="pubmed">27480325</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung JW. Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey. Korean J Pediatr. 2011;54(5):192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145902</ArticleId><ArticleId IdType="pubmed">21829409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829966</ArticleId><ArticleId IdType="pubmed">19196675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li Y, Nair H, Campbell H. Time-varying Association between severe respiratory Syncytial Virus infections and subsequent severe asthma and wheeze and influences of age at the infection. J Infect Dis. 2022;226(Suppl 1):S38–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">34522963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledbetter J, Brannman L, Wade SW, Gonzales T, Kong AM. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants. J Med Econ. 2020;23(2):139–47.</Citation><ArticleIdList><ArticleId IdType="pubmed">31432723</ArticleId></ArticleIdList></Reference><Reference><Citation>Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143(5 Suppl):S112–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615709</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001;85(6):463–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1719001</ArticleId><ArticleId IdType="pubmed">11719328</ArticleId></ArticleIdList></Reference><Reference><Citation>Broughton S, Bhat R, Roberts A, Zuckerman M, Rafferty G, Greenough A. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants. Arch Dis Child. 2006;91(1):26–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2083105</ArticleId><ArticleId IdType="pubmed">16188957</ArticleId></ArticleIdList></Reference><Reference><Citation>Cilla G, Oñate E, Perez-Yarza EG, Montes M, Vicente D, Perez‐Trallero E. Viruses in community‐acquired pneumonia in children aged less than 3 years old: high rate of viral coinfection. J Med Virol. 2008;80(10):1843–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166914</ArticleId><ArticleId IdType="pubmed">18712820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, et al. Respiratory syncytial virus disease in preterm infants in the US born at 32–35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014;33(6):576–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4025592</ArticleId><ArticleId IdType="pubmed">24622396</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578302</ArticleId><ArticleId IdType="pubmed">31206246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdeau M, Vadlamudi NK, Bastien N, Embree J, Halperin SA, Jadavji T, et al. Pediatric RSV-Associated hospitalizations before and during the COVID-19 pandemic. JAMA Netw Open. 2023;6(10):e2336863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10551765</ArticleId><ArticleId IdType="pubmed">37792376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Kim HY, Lee M, Ahn JG, Baek JY, Kim MY, et al. Respiratory Syncytial Virus Outbreak without Influenza in the Second Year of the Coronavirus Disease 2019 pandemic: a National Sentinel Surveillance in Korea, 2021–2022 season. J Korean Med Sci. 2022;37(34):e258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9424700</ArticleId><ArticleId IdType="pubmed">36038956</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang X, Cong B, Deng S, Feikin DR, Nair H. Understanding the potential drivers for respiratory Syncytial Virus Rebound during the Coronavirus Disease 2019 Pandemic. J Infect Dis. 2022;225(6):957–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807230</ArticleId><ArticleId IdType="pubmed">35030633</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltezou HC, Papanikolopoulou A, Vassiliu S, Theodoridou K, Nikolopoulou G, Sipsas NV. COVID-19 and respiratory virus co-infections: a systematic review of the literature. Viruses. 2023;15(4):865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10142898</ArticleId><ArticleId IdType="pubmed">37112844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim L, Kim J-A, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151963</ArticleId><ArticleId IdType="pubmed">25078381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review &amp; Assessment (HIRA) database for research. J Lipid Atheroscler. 2022;11(2):103–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133780</ArticleId><ArticleId IdType="pubmed">35656154</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of Observational studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25046131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha JSYKSKIGJ. Sentinel Surveillance results for Influenza and Acute Respiratory infections during the Coronavirus Disease 2019 Pandemic. Public Health Wkly Rep. 2023;16(20):597–612.</Citation></Reference><Reference><Citation>Group I-RS. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9724660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Abdel-Halim L, Valik JK, Alfvén T, Nauclér P. Outcomes of Pediatric SARS-CoV-2 Omicron infection vs influenza and respiratory Syncytial Virus infections. JAMA Pediatr. 2024;178(2):197–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10751651</ArticleId><ArticleId IdType="pubmed">38147325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Togo K, Agosti Y, McLaughlin JM. Epidemiology of respiratory syncytial virus in Japan: a nationwide claims database analysis. Pediatr Int. 2022;64(1):e14957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9300113</ArticleId><ArticleId IdType="pubmed">34388302</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantenberg JR, van Aalst R, Zimmerman N, Limone B, Chaves SS, La Via WV, et al. Medically attended illness due to respiratory syncytial virus infection among infants born in the United States between 2016 and 2020. J Infect Dis. 2022;226(Supplement2):S164–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377038</ArticleId><ArticleId IdType="pubmed">35968869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton MA, Calzavara A, Emerson SD, Djebli M, Sundaram ME, Chan AK, et al. Validating International classification of Disease 10th revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations. PLoS ONE. 2021;16(1):e0244746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7790248</ArticleId><ArticleId IdType="pubmed">33411792</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesen CK, van Wijhe M, Tong S, Fernández LV, Heikkinen T, van Boven M, et al. Age-specific estimates of respiratory syncytial virus-associated hospitalizations in 6 European countries: a time series analysis. J Infect Dis. 2022;226(Supplement1):S29–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">35748871</ArticleId></ArticleIdList></Reference><Reference><Citation>OECD, OECD Health Statistics 2023; 2023. https://www.oecd.org/health/health-data.htm</Citation></Reference><Reference><Citation>Lee JY, Park J, Lee M, Han M, Lim SM, Baek JY et al. Rising Public Cost of Preterm Infant Hospitalization: A nationwide observational study in South Korea. 2023.</Citation></Reference><Reference><Citation>Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5):127–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615711</ArticleId></ArticleIdList></Reference><Reference><Citation>Doucette A, Jiang X, Fryzek J, Coalson J, McLaurin K, Ambrose CS. Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997–2012. PLoS ONE. 2016;11(4):e0152208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4822775</ArticleId><ArticleId IdType="pubmed">27050095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouyon J-B, Roze J-C, Guillermet-Fromentin C, Glorieux I, Adamon L, Di Maio M, et al. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at &lt; 33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect. 2013;141(4):816–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3594836</ArticleId><ArticleId IdType="pubmed">22697130</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, et al. Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009–2019: a study of the national (nationwide) inpatient sample. J Infect Dis. 2022;226(Supplement2):S154–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377046</ArticleId><ArticleId IdType="pubmed">35968878</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, et al. Respiratory syncytial virus burden and healthcare utilization in United States infants &lt; 1 year of age: study of nationally representative databases, 2011–2019. J Infect Dis. 2022;226(Supplement2):S184–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377028</ArticleId><ArticleId IdType="pubmed">35968879</ArticleId></ArticleIdList></Reference><Reference><Citation>Packnett ER, Winer IH, Oladapo A, Wojdyla M. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration. Hum Vaccin Immunother. 2023;19(2):2252289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10578184</ArticleId><ArticleId IdType="pubmed">37828711</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. J Perinatol. 2016;36(11):990–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5090170</ArticleId><ArticleId IdType="pubmed">27490190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi N, Palmer L, Chu B-C, Katkin JP, Hall CB, Masaquel AS, et al. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. J Med Econ. 2011;14(3):335–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">21524154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864404</ArticleId><ArticleId IdType="pubmed">20399493</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi EJ. Policy measures for the management of Health statistics on premature live births. Health Welf Forum. 2023;2023(3):81–95.</Citation></Reference><Reference><Citation>Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023;21(3):195–210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9574826</ArticleId><ArticleId IdType="pubmed">36253478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YK, Song SH, Ahn B, Lee JK, Choi JH, Choi S-H et al. Shift in clinical epidemiology of human parainfluenza virus type 3 and respiratory syncytial virus B infections in Korean children before and during the COVID-19 pandemic: a multicenter retrospective study. J Korean Med Sci. 2022;37(28).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9294504</ArticleId><ArticleId IdType="pubmed">35851860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HM, Lee EJ, Lee NJ, Woo SH, Kim JM, Rhee JE, et al. Impact of coronavirus disease 2019 on respiratory surveillance and explanation of high detection rate of human rhinovirus during the pandemic in the Republic of Korea. Influenza Other Respir Viruses. 2021;15(6):721–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446939</ArticleId><ArticleId IdType="pubmed">34405546</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang Y-C, Lin K-P, Wang L-A, Yeh T-K, Liu P-Y. The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review. Infect Drug Resist. 2023;16:661–675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9897071</ArticleId><ArticleId IdType="pubmed">36743336</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics. Updated AAP guidance recommends longer breastfeeding due to benefits 2022. https://publications.aap.org/aapnews/news/20528/Updated-AAP-guidance-recommends-longer</Citation></Reference><Reference><Citation>Jang MJ, Kim YJ, Hong S, Na J, Hwang JH, Shin SM, et al. Positive association of breastfeeding on respiratory syncytial virus infection in hospitalized infants: a multicenter retrospective study. Clin Exp Pediatr. 2020;63(4):135–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170789</ArticleId><ArticleId IdType="pubmed">32024328</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for Prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837–46.</Citation><ArticleIdList><ArticleId IdType="pubmed">35235726</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>